Piper cubeba Demonstrates Anti-Estrogenic and Anti-Inflammatory Properties

Abstract

This present study aims to investigate if P9605, an ethanolic extract of Piper cubeba L, exhibits anti-estrogenic and anti-inflammatory properties. We found that P9605 significantly inhibited growth induced by β-estradiol in MCF-7, a human breast cancer cell line. It inhibited aromatase activity, which is responsible for transforming androgens into estrogens. Competitive binding assays also indicated P9605 binding to both human recombinant estrogen a and β receptors. Furthermore, this extract inhibited the activities of cyclo-oxygenases (COX-1 and COX-2) and 5-lipo-oxygenase (5-LOX), also it attenuated the induction of interleukin 6 (IL-6) in differentiated THP-1 cells stimulated by lipopolysaccharide (LPS). Taken together with our previous results, P9605 possesses anti-androgenic, anti-estrogenic and anti-inflammatory properties. These results support the potential use of P9605 in phytotherapy against benign prostatic hyperplasia (BPH).

Key words

Piper cubeba (L.) - Piperaceae - anti-estrogenic - anti-inflammatory - aromatase - estrogen receptors

References

• 1 Levy A, Samraj G P. Benign prostatic hyperplasia: when to ”watch and wait,” when and how to treat.  Cleve Clin J Med. 2007;  74 (Suppl 3) S15-20
• 2 Oesterling J E. Benign prostatic hyperplasia. Medical and minimally invasive treatment options.  N Engl J Med. 1995;  332 99-109
• 3 Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms.  Planta Med. 2001;  67 489-500
• 4 Takase Y, Levesque M H, Luu-The V, El-Alfy M, Labrie F, Pelletier G. Expression of enzymes involved in estrogen metabolism in human prostate.  J Histochem Cytochem. 2006;  54 911-21
• 5 Mobbs B G, Johnson I E, Connolly J G, Thompson J. Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content?.  J Steroid Biochem. 1983;  19 1279-90
• 6 Nickel J C, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia.  BJU Int. 1999;  84 976-81
• 7 Nickel J C. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis.  Curr Opin Urol. 2006;  16 5-10
• 8 St Sauver J L, Jacobson D J, McGree M E, Lieber M M, Jacobsen S J. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia.  Am J Epidemiol. 2006;  164 760-8
• 9 Usia T, Watabe T, Kadota S, Tezuka Y. Potent CYP3A4 inhibitory constituents of Piper cubeba. .  J Nat Prod. 2005;  68 64-8
• 10 Sherwood E R, Van Dongen J L, Wood C G, Liao S, Kozlowski J M, Lee C. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.  Br J Cancer. 1998;  77 855-61
• 11 Zhao X Y, Ly L H, Peehl D M, Feldman D. 1Alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.  Endocrinology. 1997;  138 3290-8
• 12 Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia?.  Curr Opin Urol. 2006;  16 25-9
• 13 Horoszewicz J S, Leong S S, Kawinski E, Karr J P, Rosenthal H, Chu T M. et al . lLNCaP model of human prostatic carcinoma.  Cancer Res. 1983;  43 1809-18
• 14 Veldscholte J, Berrevoets C A, Mulder E. Studies on the human prostatic cancer cell line LNCaP.  J Steroid Biochem Mol Biol. 1994;  49 341-6
• 15 Veldscholte J, Berrevoets C A, Brinkmann A O, Grootegoed J A, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation.  Biochemistry. 1992;  31 2393-9
• 16 Fuqua S A, Schiff R, Parra I, Friedrichs D E, Su S L, McKee D D. et al . Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer.  Cancer Res. 1999;  59 5425-8
• 17 Stöhr J R, Xiao P G, Bauer R. Constituents of Chinese Piper species and their inhibitory activity on prostaglandin and leukotriene biosynthesis in vitro. .  J Ethnopharmacol. 2001;  75 133-9
• 18 Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?.  Eur Urol. 2007;  51 1202-16
• 19 Buck A C. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action.  J Urol. 2004;  172 1792-9